Pembrolizumab: all 1,753 studies that test it
Page 11 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLCompletedNCT02362997Phase 2Results posted
- Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)Active, not recruitingNCT02362594Phase 3Results posted
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- Pembrolizumab in Treating Patients With Advanced Uveal MelanomaTerminatedNCT02359851Phase 2Results posted
- MK-3475 as Maintenance Therapy in Extensive Stage SCLCCompletedNCT02359019Phase 2Results posted
- A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)CompletedNCT02358031Phase 3Results posted
- Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder CancerCompletedNCT02351739Phase 2Results posted
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:CompletedNCT02348008Phase 1/2Results posted
- Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLCCompletedNCT02343952Phase 2Results posted
- Pembrolizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02337686Phase 2Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)CompletedNCT02335424Phase 2Results posted
- Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
- Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple MyelomaCompletedNCT02331368Phase 2Results posted
- ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)CompletedNCT02325557Phase 1/2Results posted
- MK-3475/BCG in High Risk Superficial Bladder CancerCompletedNCT02324582Phase 1Results posted
- Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung CancerCompletedNCT02316002Phase 2Results posted
- Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade GliomasCompletedNCT02313272Phase 1Results posted
- Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With EnzalutamideActive, not recruitingNCT02312557Phase 2Results posted
- Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV MelanomaCompletedNCT02306850Phase 2Results posted
- RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic CancersCompletedNCT02303990Phase 1Results posted
- SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced SarcomasCompletedNCT02301039Phase 2Results posted
- Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT02296684Phase 2Results posted
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT02289222Phase 1/2Results posted
- Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and NeckCompletedNCT02289209Phase 2Results posted
- Pembrolizumab in Treating Patients With Advanced Merkel Cell CancerCompletedNCT02267603Phase 2Results posted
- A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal CancerCompletedNCT02260440Phase 2Results posted
- A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)CompletedNCT02256436Phase 3Results posted
- Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)CompletedNCT02255097Phase 2Results posted
- Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)CompletedNCT02252042Phase 3Results posted
- Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary SyndromeCompletedNCT02243579Phase 2Results posted
- Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)CompletedNCT02220894Phase 3Results posted
- A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)TerminatedNCT02212730Phase 1Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)CompletedNCT02180061Phase 1Results posted
- A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)CompletedNCT02179918Phase 1Results posted
- Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/2Results posted
- Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)CompletedNCT02142738Phase 3Results posted
- A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell CancerCompletedNCT02133742Phase 1Results posted
- Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)CompletedNCT02132754Phase 1Results posted
- A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)CompletedNCT02130466Phase 1/2Results posted
- Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast CancerCompletedNCT02129556Phase 1/2Results posted
- MK-3475 in Melanoma and NSCLC Patients With Brain MetastasesCompletedNCT02085070Phase 2Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)CompletedNCT02054806Phase 1Results posted
- Immunotherapy Study for Patients With Stage IV MelanomaTerminatedNCT02054520Phase 2Results posted
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)CompletedNCT02039674Phase 1/2Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)CompletedNCT02007070Phase 1Results posted
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaCompletedNCT01993719Phase 2Results posted
- Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)CompletedNCT01905657Phase 2/3Results posted
- Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)CompletedNCT01876511Phase 2Results posted
- Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)CompletedNCT01848834Phase 1Results posted
- Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)CompletedNCT01840579Phase 1Results posted
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)CompletedNCT01704287Phase 2Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results posted
- Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLCSuspendedNCT07639242Phase 2
- Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerActive, not recruitingNCT07523763Phase 2
- Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)WithdrawnNCT07513324Phase 2
- Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesWithdrawnNCT07511972Phase 2
- IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaCompletedNCT07436390Not applicable
- Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)Active, not recruitingNCT07376317Phase 2
- Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnNCT07353957Phase 2
- Pembrolizumab + MRGOO3 as Neoadjuvant in NPCActive, not recruitingNCT07267338Phase 2
- A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer ParticipantsActive, not recruitingNCT07180862Phase 1
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 3
- A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06932952Phase 1
- PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsActive, not recruitingNCT06906822Phase 2
- A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
- Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCCSuspendedNCT06860386Phase 2
- Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT06790966Phase 3
- Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingNCT06784648Phase 1/2
- A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell CarcinomaTerminatedNCT06716853Phase 1/2
- A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Active, not recruitingNCT06698042Phase 3
- A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationTerminatedNCT06682806Phase 2
- Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingNCT06635824Phase 3
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerActive, not recruitingNCT06632327Phase 3
- Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast CancerCompletedNCT06604858Phase 2
- Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT06580054Phase 2
- Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1Active, not recruitingNCT06579196Phase 1/2
- Perioperative Immunotherapy for NSCLC (ECTOP-1030)WithdrawnNCT06572722Phase 2
- LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06558799Phase 2
- Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomasActive, not recruitingNCT06557889Phase 2
- Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerWithdrawnNCT06528210Phase 2
- A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)Active, not recruitingNCT06504394Phase 2
- A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic CancerWithdrawnNCT06498518Phase 2
- A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)Active, not recruitingNCT06483334Phase 1/2
- A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)CompletedNCT06470763Phase 1/2
- PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSCompletedNCT06413095Early Phase 1
- Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06405230Phase 1/2
- A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)WithdrawnNCT06395090Phase 1/2
- Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT06381154Phase 2
- Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic CancerCompletedNCT06378047Phase 1
- PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedNCT06366451Early Phase 1
- PSMA Therapy and Immunotherapy in Kidney CancerWithdrawnNCT06361810Phase 1/2
- ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCTerminatedNCT06351332Phase 1
- A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT06348199Phase 3
- Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.Status unknownNCT06344715Phase 1
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsActive, not recruitingNCT06328673Phase 1
- Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaCompletedNCT06320353Phase 3
- Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingNCT06318286Phase 2
- A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerActive, not recruitingNCT06311721Phase 3
- Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06308913Early Phase 1